The first case has been discussed elsewhere.17 In the second case (a patient with metastatic metaplastic breast cancer), genomic profiling of the residual tumor revealed a PIK3CA H1047R mutation and drug profiling predicted a response to alpelisib; multiple other targeted agents including everolimus, and chemotherapies did not appear to be effective. Here, PIK3CA is linked to breast cancer.